New paradigm for expediting drug development in Asia.

Area of Science:

• Pharmacology
• Drug Development
• Regulatory Science

Background:

• Asian regulatory bodies often mandate Phase I ethnic sensitivity studies (ESS) before global Phase II/III trials.
• Existing ESS protocols face inherent limitations in detecting potential interethnic variations.

Purpose of the Study:

• To critically evaluate the utility and limitations of Phase I ESS in Asian populations.
• To propose an alternative global drug development paradigm for Asian market inclusion.

Main Methods:

• Review of recent new drug applications (NDAs) submitted to Japanese and Chinese regulatory agencies.
• Analysis of the value and limitations of separate ESS in Asian populations based on NDA data.

Main Results:

• The study found limited value in conducting separate ESS for identifying interethnic differences in Asian populations.
• Extrapolation of existing safety, pharmacokinetic (PK), and pharmacogenetic (PG) data may be feasible.

Conclusions:

• A revised global drug development strategy is proposed, potentially eliminating the need for separate ESS.
• This new paradigm could expedite drug development for Asian markets while meeting regulatory demands.